Sammy J. Farah - 20 Jul 2023 Form 3 Insider Report for Turnstone Biologics Corp. (TSBX)

Role
President & CEO, Director
Signature
/s/ P. Joseph Campisi, Jr., Attorney-in-Fact
Issuer symbol
TSBX
Transactions as of
20 Jul 2023
Transactions value $
$0
Form type
3
Filing time
20 Jul 2023, 21:50:14 UTC
Next filing
17 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TSBX Employee Stock Option (Right to Buy) 20 Jul 2023 Common Stock 114,958 $1.51 Direct F1
holding TSBX Employee Stock Option (Right to Buy) 20 Jul 2023 Common Stock 25,320 $1.59 Direct F1
holding TSBX Employee Stock Option (Right to Buy) 20 Jul 2023 Common Stock 92,679 $1.59 Direct F1
holding TSBX Employee Stock Option (Right to Buy) 20 Jul 2023 Common Stock 304,653 $9.34 Direct F1
holding TSBX Employee Stock Option (Right to Buy) 20 Jul 2023 Common Stock 238,304 $10.7 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.
F2 One fourth (1/4th) of the shares subject to the option award vested on January 20, 2023, and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney